MedTrace Logo

Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients

NCT04054999 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2024-06-24

Study results available
· View outcomes & findings →

Summary

This study will evaluate if Hydroxocobalamin may be a new and possibly superior treatment for refractory vasoplegic syndrome during liver transplant surgery.

Conditions

  • Vasoplegic Syndrome
  • Liver Transplant; Complications

Interventions

DRUG

Hydroxocobalamin

Hydroxocobalamin (Cyanokit): 5g IV infusion over 15 minutes

DRUG

Methylene Blue

Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes

Sponsors & Collaborators

Principal Investigators

  • Sher-Lu Pai, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-30
Primary Completion
2023-02-27
Completion
2024-02-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04054999 on ClinicalTrials.gov